These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 30947669)

  • 1. Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed.
    Zanjirband M; Rahgozar S
    Curr Drug Targets; 2019; 20(11):1091-1111. PubMed ID: 30947669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule agents targeting the p53-MDM2 pathway for cancer therapy.
    Wang W; Hu Y
    Med Res Rev; 2012 Nov; 32(6):1159-96. PubMed ID: 23059763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
    Zhao Y; Aguilar A; Bernard D; Wang S
    J Med Chem; 2015 Feb; 58(3):1038-52. PubMed ID: 25396320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.
    Gupta AK; Bharadwaj M; Kumar A; Mehrotra R
    Top Curr Chem (Cham); 2017 Feb; 375(1):3. PubMed ID: 27943171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer.
    Patel S; Player MR
    Expert Opin Investig Drugs; 2008 Dec; 17(12):1865-82. PubMed ID: 19012502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule inhibitors of the p53-MDM2 interaction.
    Vu BT; Vassilev L
    Curr Top Microbiol Immunol; 2011; 348():151-72. PubMed ID: 21046355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural product MDM2 inhibitors: anticancer activity and mechanisms of action.
    Qin JJ; Nag S; Voruganti S; Wang W; Zhang R
    Curr Med Chem; 2012; 19(33):5705-25. PubMed ID: 22830335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of p53 in cancer drug resistance and targeted chemotherapy.
    Hientz K; Mohr A; Bhakta-Guha D; Efferth T
    Oncotarget; 2017 Jan; 8(5):8921-8946. PubMed ID: 27888811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting MDM2-p53 interaction for cancer therapy: are we there yet?
    Nag S; Zhang X; Srivenugopal KS; Wang MH; Wang W; Zhang R
    Curr Med Chem; 2014; 21(5):553-74. PubMed ID: 24180275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy.
    Liu Y; Wang X; Wang G; Yang Y; Yuan Y; Ouyang L
    Eur J Med Chem; 2019 Aug; 176():92-104. PubMed ID: 31100649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wild type p53 reactivation: from lab bench to clinic.
    Selivanova G
    FEBS Lett; 2014 Aug; 588(16):2628-38. PubMed ID: 24726725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
    Sirous H; Chemi G; Campiani G; Brogi S
    Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDM2-p53 pathway in hepatocellular carcinoma.
    Meng X; Franklin DA; Dong J; Zhang Y
    Cancer Res; 2014 Dec; 74(24):7161-7. PubMed ID: 25477334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 update.
    Millard M; Pathania D; Grande F; Xu S; Neamati N
    Curr Pharm Des; 2011; 17(6):536-59. PubMed ID: 21391905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges.
    Wang S; Zhao Y; Aguilar A; Bernard D; Yang CY
    Cold Spring Harb Perspect Med; 2017 May; 7(5):. PubMed ID: 28270530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Small-Molecule Inhibitors of the p53-MDM2 Protein-Protein Interaction.
    Beloglazkina A; Zyk N; Majouga A; Beloglazkina E
    Molecules; 2020 Mar; 25(5):. PubMed ID: 32156064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
    Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
    J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [NEGATIVE REGULATORS OF TUMOR SUPPRESSOR P53 IN THE CONTEXT OF ANTICANCER THERAPY].
    Shuvalov OY; Fedorova OA; Petukhov AV; Daks AA; Vasilieva EA; Grigorieva TA; Ivanov GS; Barlev NA
    Tsitologiia; 2015; 57(12):847-54. PubMed ID: 26995961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in validating MDM2 as a cancer target.
    Rayburn ER; Ezell SJ; Zhang R
    Anticancer Agents Med Chem; 2009 Oct; 9(8):882-903. PubMed ID: 19538162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?
    Haronikova L; Bonczek O; Zatloukalova P; Kokas-Zavadil F; Kucerikova M; Coates PJ; Fahraeus R; Vojtesek B
    Cell Mol Biol Lett; 2021 Dec; 26(1):53. PubMed ID: 34911439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.